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ABSTRACT

LONGITUDINAL MODELING OF EARLY HIV BURDEN IN THE CENTRAL
NERVOUS SYSTEM
V. Diego Armengol1, Veronika Shabanova2, Lars Hagberg3, Richard Price4, Magnus
Gisslén3, Serena S. Spudich1.
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Background: The dynamics of plasma HIV replication during early infection including
establishment of a viral set-point are well-known. However, the course of HIV in the
central nervous system (CNS) after initial entry of HIV into this compartment is less
understood. Using longitudinal samples, we modeled the natural history of HIV RNA in
the cerebrospinal fluid (CSF) and plasma during early HIV prior to initiation of
antiretroviral treatment (ART).

Methods: Participants with primary HIV infection (PHI, within 12 months of initial
infection) were enrolled in prospective studies with paired longitudinal sampling of blood
and CSF conducted in San Francisco, USA, and Gothenburg, Sweden prior to test-and-

treat guidelines. This analysis incorporated all samples available over the first 3 years of
infection from visits where participants were ART-naïve. HIV RNA assays had a lower
limit of quantification of 40 copies per mL. Mean trajectory of CSF HIV RNA levels
relative to time from infection was characterized using a restricted cubic spline function
of time accounting for the correlated data within subjects. Parametric linear mixed effects
models (LME) were also estimated to account for the covariate CD4/CD8 ratio and to
confirm results from the spline analysis.

Results: The final analytical cohort included 110 PHI participants (95% male, median
age = 37, days post infection = 91 at enrollment) with 228 CSF and 247 plasma
measurements. The model shows an initial decrease in CSF HIV RNA over the first 100
days of estimated infection, after which CSF HIV RNA begins to increase at a slow rate.
Similar trends were seen in the plasma model, but at higher absolute values of HIV RNA
copies/mL and with a narrower confidence interval compared to CSF. Plasma-CSF viral
load difference declined rapidly in the first 100 days of infection. We confirmed the mean
trajectory of change in HIV RNA derived from the cubic splines approach using the
parametric LME model. Blood CD4/CD8 ratio negatively correlated with CSF HIV
RNA, as there was a 0.69 unit decrease in log10(CSF HIV RNA) for each unit increase in
the CD4/CD8 ratio (p = 0.0005).

Conclusions: The viral dynamics in the CSF of ART-naïve individuals over the first 36
months of infection support the early spread of HIV to the CNS, and indicate that HIV
replication is maintained in this compartment throughout the course of early infection

prior to ART. Early initiation of ART may limit nervous system exposure to pathogenic
effects of viral replication.
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1
INTRODUCTION

Human immunodeficiency virus (HIV) is a retrovirus which has affected over 75
million people worldwide since the start of the epidemic in the 1980s [1]. The arrival of
this epidemic was first noted as a state of severe immunodeficiency – now called
acquired immune deficiency syndrome (AIDS) – but discovery of HIV itself would
follow within 2 years of the first report of AIDS [2-4]. In the decades since its discovery,
an immense amount of research has gone into learning how the virus propagates,
strategies for preventing HIV transmission, and pharmacological treatment for people
living with HIV.

In 2015, the findings of the Strategic Timing of Antiretroviral Therapy (START)
trial were published. This randomized controlled trial showed better outcomes for HIVpositive adults who initiated antiretroviral therapy (ART) at CD4+ T cell counts of over
500 cells per mm3 compared to those who initiated ART only once their CD4+ T cell
count decreased below 350 cells per mm3 [5]. In response to the START trial, the World
Health Organization (WHO) announced new guidelines, called ‘treat-all’ (now known as
‘test-and-treat’). This change expanded treatment eligibility from 28 million people to all
37 million people estimated to be living with HIV at the time [6].

Given the extent of research into HIV, and especially from in vivo models of the
related simian immunodeficiency virus (SIV) in macaques, the progression of HIV
infection can be described in detail. Infection with HIV usually occurs when the virus
crosses a mucosal barrier and infects its main target, CD4+ T cells. Following this event,
the host CD4+ T cells produce more copies of the virus, and these virions then spread to
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the lymphatic system. It is in the lymphoid tissue (accessed via the bloodstream from the
initial draining lymph nodes) where HIV infection truly takes hold due to the presence of
greater quantities of CD4+ T cells, thus resulting in true self-propagation as the virus’ R0
exceeds 1. Migration to the gut-associated lymphoid tissue in particular causes profound
depletion of CD4+ T cells [7]. The presence of HIV-infected resting CD4+ T cells is
thought to be one reason that effective ART cannot fully ‘cure’ HIV within the human
lifespan, as these cells have half-lives exceeding 40 months [8].

Bloodborne HIV can be detected by about day 10 of infection. Exponential
replication of the virus soon follows over a period of weeks, reaching a peak of about 106
– 107 copies per mL of plasma, coinciding with an acute symptomatic period of flu-like
illness and lymphadenopathy in some individuals. This peak in plasma viral RNA is
followed by a precipitous decline and, in most individuals, the amount of virus in the
plasma reaches a low plateau, termed the ‘viral set point’ [9]. It generally takes 4-6
months to reach this set point, at which point the acute/primary phase of infection
concludes [1].

Coinciding with the decrease of plasma viral load following its early peak is the
depletion of blood CD4+ T cells, which reach a nadir at around 6 weeks post-infection.
Afterward, the CD4+ T cell count usually recovers to near-normal levels by about 12
weeks, by which point the viral load has reached its set point. However, over the
subsequent years, untreated HIV slowly depletes the body’s CD4+ T cells by creating a
state of constant activation – and subsequent death – of both CD4+ and CD8+ T cells [1].
Research has shown this T cell activation to be an independent predictor of the rate of
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CD4+ T cell decline and AIDS progression [10, 11]. Following the trajectory of the
CD4+ T cell count over time has been important for clinical care, as severe infections
become more common with counts under 350 cells per μL; one of the criteria for a
diagnosis of AIDS is a CD4+ T cell count of less than 200 cells per μL. Figure 1
summarizes these changes in plasma viral load and blood CD4+ T cell count over time
[1, 12].

Figure 1. Schematic representation of plasma viral load (red) and blood CD4+ T cell
count (blue) during the natural course of HIV infection. Adapted from Giorgi, 2011
and Deeks et al., 2015.
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Importantly, there is individual variation in the absolute value of the peak viral
load and viral set point, which can fall between a wide possible range. A greater quantity
of symptoms during primary infection has been found to be predictive of higher initial
viral loads, and severity of symptoms shows a similarly positive correlation. A greater
quantity of infectious symptoms is also associated with a higher viral set point [13].
Moreover, higher viral set points have long been known to be predictors of a poor
prognosis, and viral load is actually a more reliable predictor of progression to AIDS than
CD4+ T cell count, despite the widespread use of the latter measure in the clinical setting
[14].
Some individuals with HIV, termed ‘elite controllers’, naturally exhibit viral set
points below the limit of detection of typical assays, which usually corresponds to fewer
than 50 copies of HIV RNA per mL plasma. One of the leading theories attempting to
explain this phenomenon centers around CD8+ T cells, as these cells have been shown to
inhibit viral replication during primary infection. This likely does not fully explain the
phenomenon, as some elite controllers lack an HIV-specific CD8+ T cell response, thus
more investigation will be needed to better understand the mechanisms behind elite
controllers’ natural viral suppression [15, 16].

HIV has long been known to affect the central nervous system (CNS) [17], with
documented effects including cognitive impairment, inflammation, neuronal damage, and
cortical thinning [18-22]. Additionally, preferential loss of volume in the putamen has
been seen in individuals with early HIV infection [23]. The range of neurological
symptoms seen in individuals living with HIV, termed HIV-associated neurocognitive
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disorder (HAND), includes asymptomatic neurocognitive impairment, mild
neurocognitive disorder, and HIV-associated dementia (HAD) in the most severe cases.
While ART is the only known way to impede the progression of HAND, these symptoms
can still occur in individuals who are receiving treatment [24]. In a study of macaques
with SIV, ART was found to prevent the development of SIV encephalitis when
compared to infected macaques that did not receive treatment, and even resulted in the
absence of virus in postmortem brain samples of treated macaques, despite the use of
ART drugs that could not cross the blood-brain barrier (BBB) [25].

Moreover, HIV is a neurotropic virus which leads to infection of cells within the
CNS, and the neuropathogenesis of this process is an area of active investigation. The
process is thought to begin with inflammation and breakdown of the BBB, with one study
finding that some individuals are susceptible to severe disruption of the BBB persisting
beyond 1000 days after infection (as measured by elevations in the cerebrospinal fluid
[CSF] to serum albumin quotient), and that this phenomenon is associated with changes
in CSF biomarkers indicative of greater CNS involvement. The authors also noted that
initiation of ART (at a median of 225 days after infection) successfully suppressed viral
replication in both CSF and plasma, as well as reduced signs of CNS inflammation, but
did not change BBB permeability [26]. While systemic inflammation is likely responsible
for the initial sequence of events resulting in HIV translocation across the BBB and
neurodegeneration, other mechanisms are suspected to contribute to the development of
HAND, such as changes to the release and uptake of glutamate. Specifically, the HIV
proteins tat and envelope glycoprotein gp120 can stimulate glutamate release and
decrease its synaptic uptake, which, along with phosphorylation of glutamate receptors
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and incomplete glutamate recycling via the glutamate-glutamine shuttle, contributes to
augmented glutamate toxicity [24].

Despite the reduction in CSF viral load often seen after the initiation of ART,
other studies have shown that HIV is capable of establishing a viral ‘reservoir’ in the CSF
that, in some individuals, can persist even in those receiving long-term ART [27, 28].
This phenomenon, termed ‘CSF escape’, has been associated with worsening neurologic
function and thus is implicated in the development of HAND [29-32].

When CSF escape occurs, it is posited to be caused by HIV remaining in CNS
microglia, resulting in reseeding of other tissues and contributing to ART resistance;
accordingly, these cells have become a focus of intense research [33]. While HIV has
also been detected in astrocytes in some studies, whether they can be considered cellular
reservoirs of the virus remains controversial [34, 35]. Regardless, the presence of viral
reservoirs such as that seen in the CNS impede eradication of the virus and thus prevent a
true cure.

As previously discussed, the dynamics of HIV replication in the blood plasma
during acute infection are well-known [36]. Similar dynamics of HIV infection have been
studied in other tissues of the body, which creates viral compartments. This process has
been documented in the CNS and genital tract, but also likely occurs in the gut, lung,
liver, kidney, and breast milk [37].

One example is the semen, where HIV viral load was found to have an early peak,
similar to that seen in plasma, in one prospective cohort study of men with acute HIV
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infection in Lilongwe, Malawi. This was followed by a stable, suppressed level.
However, the viral load in plasma peaked earlier than that of the semen (~17 days postinfection compared to ~30 days in semen) [38]. The absolute values of both the estimated
peak and viral set point in the semen were found to be lower than those in the plasma
[39].

Studies of HIV in the CNS rely primarily on brain tissue at autopsy or on CSF
analysis. These have led, for example, to the discovery that the virus in the brains of
people with HIV-associated dementia is genetically distinct from the virus in those
without HIV-associated dementia [40]. However, in order to study HIV in the CNS of
living people, CSF must be analyzed. Studies using CSF have led to similar discoveries
showing that viral populations in the CSF and plasma are genetically distinct from one
another [41, 42].

Prior studies, such as those involving the RV254/SEARCH010 cohort, a large
cohort of mostly male participants in Bangkok, Thailand identified during acute HIV
infection, have investigated the neuropathogenesis of HIV. In one such prospective study,
investigators noted that HIV RNA could be detected in the CSF of participants as early as
8 days after infection with the virus. Inflammation of the CNS was noted in some
participants, whose CSF showed elevations in inflammatory markers such as neopterin,
monocyte chemotactic protein/CCL2, and interferon γ–induced protein 10/CXCL-10
levels. Signs of brain parenchymal inflammation were also noted on magnetic resonance
spectroscopy (MRS) – specifically, higher choline/creatine in the occipital gray matter at
the middle posterior cingulate gyrus – when these participants were compared to
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individuals living with chronic HIV as well as HIV-negative Thai controls. They also
noted that headache, while a common symptom in the acute phase of infection, was not
accompanied by any other acute neurological signs or symptoms [43].

In contrast, a different observational study combining cohorts of participants with
primary HIV infection – including the Primary Infection Stage CNS Events Study
(PISCES) cohort in San Francisco, USA as well as cohorts in Gothenburg, Sweden,
Milan, Italy, and Sydney, Australia – found that some neurological symptoms do develop
during primary infection, such as encephalitis, clinical meningitis, lower motor neuron
facial palsy, distal paresthesia, photophobia with intense headache, acute painful
polyradiculopathy, and brachial neuritis [44]. Another study, also involving the PISCES
cohort, found that major depressive disorder was prevalent among participants during
primary infection, with greater somatic symptoms than cognitive/affective symptoms and
decreased vigor scores relative to controls, and that these findings did not change over
longitudinal follow-up prior to initiation of ART [45].

Notably, viral compartmentalization is not a phenomenon solely seen with HIV.
Examples in the literature include the lifelong persistence of BK virus in kidney tubule
epithelial cells and urinary tract epithelial cells [46], the presence of hepatitis C virus in
extrahepatic tissue such as the B cells and macrophages of the colon [47] as well as
platelets [48], and the establishment of reservoirs of human papillomavirus in the hair
follicle stem cells of healthy individuals [49].

The JC virus has even been shown to undergo a dynamic reorganization process
that is compartment-specific: in individuals with progressive multifocal
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leukoencephalopathy (PML), the viral population in the CSF is composed of a mixture of
viral variants that is correlated to that seen in plasma, but significantly different from the
population in urine, which mostly consists of the archetypal JC virus strain [50]. In a case
report of an immunocompromised person who died from PML, autopsy showed distinct
viral rearrangements in different regions of the brain, suggesting multiple independent
origins for the lesions [51].

In comparison to plasma, the natural progression of HIV penetration into the CSF
is less understood. Despite our knowledge of CSF escape, important questions remain
regarding at which point during the course of infection this viral reservoir is established,
prior to initiation of ART. A detailed analysis of this process would be an important
further step in continuing to understand the natural course of HIV and its establishment of
a CNS reservoir. We undertook a prospective longitudinal study of early infection in
treatment-naïve participants and characterized the trajectory of change of HIV viral load
in the CSF.
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STATEMENT OF PURPOSE

We aimed to create a mathematical model to describe the natural dynamics of
HIV in the CSF during early infection. To do so, we used data from a prospective
longitudinal observational study of individuals identified during early infection and
conducted an analysis using a subset of treatment-naïve participants. Once a model for
CSF HIV burden during early infection was created, we compared it to the dynamics in
plasma. We expected that the peak viral load would be lower than that found in the
plasma and would occur later during the course of infection. However, we anticipated
that the initial peak may not be fully determinable based on the timing of baseline visits
in the cohort. We also expected the viral set point for CSF HIV burden to be established
early in the course of infection and to remain stable over time, as is seen in the plasma
model. Moreover, we created models for the plasma-CSF viral load difference and the
blood CD4/CD8 T cell ratio over the same period of time. The plasma-CSF viral load
difference was expected to remain positive as viral load is generally higher in the plasma
relative to CSF. The CD4/CD8 ratio was expected to decrease as plasma viral load
increases, and we predicted the same relationship would be true with CSF viral load.

Specific Aims

1. Create a nonparametric model for CSF HIV RNA dynamics using longitudinal
data.
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a. Model plasma HIV burden using the same longitudinal data and compare
the dynamics of HIV distribution in these two compartments.
b. Model the logarithmic difference between plasma and CSF viral loads
using the same longitudinal data.
c. Model the blood CD4/CD8 ratio using the same longitudinal data and
describe trends.
2. Create a parametrized model to approximate the nonparametric model from
Specific Aim 1.
a. Use the nonparametric model to estimate potential knots in parametrized
model.
b. Determine whether potential covariates such as CD4/CD8 ratio and
polynomials of time since infection are significantly associated with CSF
viral load.
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METHODS

Student Contributions

All data analysis (described below) and generation of figures was conducted by
the author (V. Diego Armengol) with guidance from Veronika Shabanova, PhD and
Serena Spudich, MD, MA. This included application of exclusion criteria to the overall
set of data to select an appropriate set of data from cohorts of ART-naïve participants, as
well as the generation of both the nonparametric longitudinal models and the
parametrized models. This analysis uses pre-existing data from larger observational
studies conducted in San Francisco, USA by Serena Spudich, MD, MA and Richard
Price, MD, and in Gothenburg, Sweden by Lars Hagberg, MD, PhD and Magnus Gisslén,
MD, PhD.

Ethics Statement

Participation in the longitudinal observational studies which produced the data
used in this analysis (described below) was entirely voluntary and all participants gave
written informed consent. Participants who were identified during primary HIV infection
were enrolled in prospective studies and returned for as many repeat blood draws, lumbar
punctures, neuroimaging, and cognitive studies as they wished. Participants were also at
liberty to consent to some measurements but not others at each encounter (e.g., during a
given study visit they could consent to a blood draw but not a lumbar puncture).
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Moreover, the collection of this data had no bearing on their individual medical treatment
for HIV or otherwise.

As data collection occurred prior to the application of universal test-and-treat
guidelines, it is important to note that participation in this study had no influence on the
date of ART initiation. This resulted in a unique subset of observational data from
participants who remained ART-naïve, which can no longer be recreated in the age of
test-and-treat.

Participants and Data Collection

This is a secondary analysis of data from the PISCES cohort in San Francisco,
USA, and a complementary study of individuals with primary HIV infection in
Gothenburg, Sweden, which have been previously described [26, 44, 52]. Briefly,
participants were originally enrolled in neurological early HIV infection studies between
November 1986 and February 2014 at 2 institutions: the University of California, San
Francisco and the University of Gothenburg in Sweden. All potential participants were
screened for primary HIV-1 infection with the Serological Testing Algorithm for Recent
HIV Seroconversion (STARHS) [53, 54].
Individuals with early infection – as demonstrated by a recent positive HIV-1
nucleic acid test, and a negative test in the prior 12 months, or less commonly an
antibody test indicating recent infection – were invited to participate. Participants with an
enzyme immunoassay result indicating infection within the past 6 months were also
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offered enrollment. All participants were ART-naïve at enrollment. An approximate date
of infection for each participant was estimated according to standard clinical and
laboratory parameters (date of HIV transmission from donor to host was estimated as 14
days prior to the onset of any symptoms of an acute retroviral syndromes, or as the
halfway point between the last negative and first positive test) [55]. Participants in the
PISCES cohort were presumed to be infected with clade B viruses, whereas HIV subtype
information was collected for some participants in the Gothenburg cohort given their
more diverse geographic origin [44].

Study visits were scheduled at baseline, 6 weeks, and every 6 months thereafter,
although there was participant variation in the timing and duration of follow-up. CSF and
blood specimens were obtained and processed at each visit as previously described [19,
45, 56, 57]. HIV RNA was measured in both the CSF supernatant (cell-free fraction of
CSF) and blood plasma using the Roche Amplicor Monitor assay at both sites, with a
quantitation limit of 50 copies/mL and a detection limit of 20 copies/mL [52, 58].

Viral load results for both CSF and plasma were calculated as log10(HIV RNA
copies/mL). Detectable results less than 50 copies/mL were reported with a value of 1.69
(equivalent to log10 49). Additionally, a plasma-CSF viral load difference was calculated,
which is equivalent to log10(HIV RNA copies per mL CSF) – log10(HIV RNA copies per
mL plasma). Analysis of CSF and flow cytometry for blood CD4+ and CD8+ T
lymphocyte counts were performed as previously described, along with testing for other
biomarkers not applicable to the current analysis [52].
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Statistical analysis

Continuous variables were summarized using means with standard deviations or
medians with Intra Quartile Range (IQR: 25th percentile, 75th percentile), while
categorical variables were summarized with frequencies and percentages. The mean
trajectory of CSF HIV RNA levels relative to time from initial HIV transmission was
characterized using a restricted cubic spline function of the time variable accounting for
the correlated data within subjects, with the fit of the model bootstrapped 1000 times,
treating a subject as a cluster [59-63]. The simultaneous 95% confidence region for the
entire regression curve was also estimated accounting for the subject clusters and plotted
relative to time since infection [64].

Data analysis was conducted using R [65] and function rm.boot in the package
Hmisc [66]. Parametric linear mixed effects (LME) models with a knot at 100 days and
time effect up to the third-degree polynomial before and after the knot were also
estimated to account for the covariate CD4/CD8 ratio and to confirm the results from the
spline analysis. Nested models for the different polynomial degrees of time were
compared using the likelihood ratio test (LRT).

We chose among a random intercept model for the covariance and an additional
random slope effect using the LRT with a mixture chi-square distribution. The estimation
of parameters in the LMEs and the splines was implemented using the full or restricted
maximum likelihood approach, which made it possible to keep all subjects in the model
by treating the missing outcome values as missing at random (MAR) [67]. The same
approach was used to characterize plasma HIV RNA levels, the plasma-CSF HIV RNA

16
level difference, and blood CD4/CD8 ratio. The R package nlme [68] was used to fit the
LMEs.

To quantify the variability among CSF viral load measurements, we calculated
and plotted a semivariogram for possible pairs of time points. In the model for the mean
of the outcome we used variables for time since infection (linear and quadratic), time
after 100 days of infection (linear, quadratic and cubic), and CD4/CD8 ratio. The plot
revealed proportionate contributions from a possible measurement error, serial withinperson correlation in time, and between-person variability, i.e., variance of random
effect(s). Once it was revealed that the majority of variability in the outcome was due to
the subject-specific characteristics, an Intra Class Correlation (ICC) was estimated to
quantify the variability among subjects in the HIV RNA CSF levels as a ratio of the
variance of the random intercept to the total variance. All statistical hypotheses tests were
conducted at the two-sided alpha level of 0.05.
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RESULTS

Study participant characteristics

The original San Francisco PISCES cohort included 109 participants, while the
Gothenburg primary infection CNS study included 27 participants, for a total of 136
participants. Among these participants over time, 491 total CSF specimens and CSF HIV
viral load measurements were collected. After excluding all study visits in which
participants had already begun ART, 130 participants and 246 CSF measurements
remained eligible for the analysis (Figure 2). In order to minimize the undue influence of
some observations on the statistical models, we excluded visits after 3 years postinfection, followed by manual exclusion of some CSF measurements from one participant
(who had 13 total CSF measurements over 2 years) to ensure a maximum of 7 CSF
measurements per participant. Following application of these exclusion criteria, we then
excluded all remaining participants who no longer had applicable CSF measurements
(i.e., participants who had plasma measurements without paired CSF measurements prior
to ART initiation). The final analytical cohort included 110 subjects, with 228 CSF
measurements and 247 plasma measurements. Participants overall had an average of 2.3
visits (median = 2) to contribute to the analysis.
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Figure 2. Description of sequential exclusion criteria applied to initial cohort of
participants. After excluding all study visits after the initiation of ART, excluding
visits after 3 years post-infection, ensuring a maximum of 7 CSF measurements per
participant, and excluding all remaining participants without applicable CSF
measurements after application of prior exclusion criteria, the final cohort
contained 110 participants, 228 CSF viral load measurements, and 247 plasma viral
load measurements. VL = viral load.

Table 1 shows the demographic characteristics of the participants included in this
analysis. Overall, the population was 95% male and 5% female. Despite the sex
imbalance, the female participants were retained because on empirical analysis, their CSF
viral burden over time was not systematically different from that of the male participants,
and a different physiologic response is not expected based on sex. Data on race and
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ethnicity was only collected at the San Francisco site; for that group of participants
(n=83), 71% were Caucasian, 11% were Black, and 8% were Asian, with 20%
identifying as Hispanic/Latino. HIV subtype was only determined at the Gothenburg site;
while subtype was not explicitly confirmed at the San Francisco site, all participants there
were presumed to have the HIV-B subtype.

Site 1 (n = 83)
n
%
Gender
Male
Female
N/A
Race
Caucasian
African-American/Black
Asian
American Indian/Alaska Native
Native Hawaiian/Pacific Islander
More than one race
Other, unknown or not reported
N/A
Ethnicity
Hispanic/Latino
Non Hispanic/Latino
N/A
HIV Subtype
A
A/D
B
C
CRF01_AE
CRF02_AG
CRF02_AG/G
N/A
Education (years)
Age at first visit (years)

Site 2 (n = 27)
n
%

Total (n = 110)
n
%

83
0
0

100
0
0

22
5
0

81.48
18.52
0

105
5
0

95.45
4.55
0

59
9
7
1
1
3
3
0

71.08
10.84
8.43
1.20
1.20
3.61
3.61
0

0
0
0
0
0
0
0
27

0
0
0
0
0
0
0
100

59
9
7
1
1
3
3
27

53.64
8.18
6.36
0.91
0.91
2.73
2.73
24.55

17
66
0

20.48
79.52
0

0
0
27

0
0
100

17
66
27

15.45
60
24.55

0
0
0
0
0
0
0
83

0
0
0
0
0
0
0
100
Mean (SD)
15.02 (2.48)
35.48 (9.16)

1
3.70
1
3.70
9
33.33
4
14.81
2
7.41
2
7.41
1
3.70
7
25.93
Mean (SD)
N/A
43.52 (13.04)

1
0.91
1
0.91
9
8.18
4
3.64
2
1.82
2
1.82
1
0.91
90
81.82
Mean (SD)
15.02 (2.48)
37.45 (10.76)
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Table 1. Demographic characteristics of cohort, separated by site. Site 1 =
University of California, San Francisco, USA; Site 2 = University of Gothenburg,
Sweden; SD = standard deviation.

Individual CSF viral load trajectories
On average, participants’ CSF viral loads were followed for 295 days postinfection (median = 152, minimum = 14, maximum = 1087) and their plasma viral loads
were followed were followed for an average of 320 days post-infection (median = 182,
minimum = 14, maximum = 1087). Participants had a mean of 2.07 CSF measurements
and 2.25 plasma measurements taken each (median = 2, minimum = 1, maximum = 7 for
both CSF and plasma). In total, there were 226 instances where treatment-naïve
participants had both CSF and plasma HIV RNA levels measured.

As shown in Table 2, a slight majority of the CSF viral load measurements (115
of 228, or 50.4%) were obtained during the first 6 months of infection. However, a
notable proportion of CSF viral load measurements were obtained between 1-3 years
post-infection (60 of 228, or 26.3%), supporting the longitudinal nature of this analysis.
Similar trends were also true of measurements of plasma viral load (119 of 247, or 48.2%
of measurements during the first 6 months; 73 of 247, or 30.0% of measurements
between 1-3 years post-infection) and of CD4/CD8 ratios (117 of 249, or 47.0% of
measurements during the first 6 months; 76 of 249, or 30.5% of measurements between
1-3 years post-infection).
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Table 2. Summary of median CSF and plasma viral loads, their difference, and
CD4/CD8 ratio for the first 3 years after seroconversion, grouped into 2-month
intervals. IQR = interquartile range.

Individual trajectories of CSF viral load measurements varied greatly among
participants, as quantified by an ICC=0.6589. When looking at individual trajectories,
CSF viral load appeared to initially decrease, often below the limit of detection, before
eventually rising, sometimes hundreds of days post-infection (Figure 3). As seen in
Figure 4, the total variance of log10(CSF HIV RNA) is about 0.74, which is composed of
a small measurement error. The lack of a steady increase in the semivariogram suggested
no decay in within-person correlation as time between data points increases, and
between-person variability was likely the largest contributor of variability.
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Figure 3. Trajectories of (a) plasma HIV viral loads and (b) CSF HIV viral loads of
individual participants over time when longitudinally sampled, prior to initiation of
antiretroviral therapy.

Figure 4. Semivariogram quantifying variability among CSF viral load
measurements. The x-axis represents time (in months) since infection.

Longitudinal models

The longitudinal mean trajectory of HIV viral load in the CSF using the cubic
splines approach is plotted in Figure 5 along with the 95% confidence interval. The
model shows an initial decrease in CSF viral load over the first 100 days of infection,
after which viral load begins to increase at a slow rate. The 100-day mark was noted to be
an inflection point in the model, which later guided our choice of a knot in the parametric
LME model. Similar trends were seen in the plasma viral load model, but at higher
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absolute values of HIV RNA copies/mL and with a narrower confidence interval when
compared to the CSF, especially during the early post-infection period. Accordingly, our
model of the plasma-CSF viral load difference showed a rapid decline in the first 100
days of infection, reflecting the initial higher magnitude of plasma viral load when
compared to the peak of CSF viral load. Toward the end of the 3-year period described
by the model, this difference begins to increase, driven by the increase in plasma viral
load seen over the same time period. Finally, our model of blood CD4/CD8 ratio showed
an initial trough at around 100 days, followed by a peak around 200 days, and a steady
decline thereafter. Figure 6 shows these same longitudinal models with individual data
points superimposed.
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Figure 5. Nonparametric models of (a) CSF HIV viral load, (b) plasma HIV viral
load, (c) the difference in viral load between plasma and CSF, and (d) blood
CD4/CD8 ratio over time in participants prior to antiretroviral therapy.

Figure 6. Nonparametric models of (a) CSF HIV viral load, (b) plasma HIV viral
load, (c) the difference in viral load between plasma and CSF, and (d) blood
CD4/CD8 ratio over time in participants prior to antiretroviral therapy. Individual
data points superimposed on all models.

We were able to confirm our characterization of the mean trajectory of change in
HIV viral load from the cubic splines approach using the parametric LME model with a
random intercept for each subject, which revealed a significant declining mean trend up
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to the second-degree polynomial prior to the 100-day knot and a significant increasing
mean trend which levels off over time using the third-degree polynomial after the 100day knot (Table 3). CD4/CD8 ratio was negatively correlated with CSF viral load, as
there was a 0.69 (95%CI: -1.1, -0.31) unit decrease in log10(CSF HIV RNA) for each unit
increase in the CD4/CD8 ratio (p = 0.0005). Plasma viral load was found to be
completely colinear with time and, therefore, was not a variable in the parametrized
model.

Variable Parameter
Intercept
4.877
Month
-1.343

95% CI
(-2.316, -0.3696)

p-value
0.0083

Month2
Month100

0.2418
-0.1880

(0.0235, 0.4602)
(-0.7446, 0.3687)

0.0330
0.5114

Month1002

-0.2460
6.0x10-5
-0.6919

(-0.4630, -0.0290)
(-8.833x10-5, 2.085x10-4)
(-1.070, -0.3140)

0.0291

Month1003
CD4/CD8

0.4313
0.0005

Table 3. Parameter estimates with 95% confidence intervals and p-values for the
parametric LME model of HIV viral load in the CSF. Month = time since infection
in months. Month100 = time since 100 days post-infection, in months.
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DISCUSSION

In this study, we created a longitudinal model for viral dynamics in the CSF of
ART-naïve individuals during early HIV infection, and compared these findings to the
known dynamics of HIV in plasma. Using a nonparametric smoothing cubic spline
approach for modeling the mean trajectory, also confirmed by a parametric LME model,
we described these dynamics over the first 36 months of infection. Together, these
models show that HIV is consistently detected in the CSF in early years of acute
infection.

According to our model, viral copies of HIV are present in the CSF early in the
course of infection. In fact, in these cohorts, HIV RNA was measured as early as the 14th
day of infection, which is the earliest detectable date in the STARHS algorithm. Other
studies have shown that HIV is present in the plasma and semen early during infection
and modeled the viral load over time [36, 38, 39], but such longitudinal natural history
models do not yet exist for the CSF. Djomand et al. analyzed plasma in a group of 39
high-risk men in Rio de Janeiro, Brazil who were identified in early infection; however,
only 21 participants in the cohort had viral loads measured within 6 months of estimated
seroconversion. As the study estimated date of seroconversion based on repeated testing
every 6 months with individuals who were initially seronegative, it was impossible to
obtain viral loads as early during infection as we have presented. However, reassuringly,
they did note a steep decline in CD4 count approximately 200 days post-seroconversion,
which is reflected in our model of CD4/CD8 ratio [36].
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Our choice to place a 100-day knot in the parametric LME model is supported by
previous findings. Stekler et al., who studied longitudinal seminal and plasma viral loads
in 89 men in Seattle, USA who were ART-naïve at the time of initial specimen
collection, noted that while there was insufficient data to estimate the exact day at which
a viral set point was established, sensitivity analysis determined it occurred by day 100
[39].

In contrast, Pilcher et al. analyzed plasma and semen in a cohort of 16 men in
Lilongwe, Malawi with acute HIV infection, estimating that peak viral load occurs at
approximately 17 days post-seroconversion in the plasma and at 30 days postseroconversion in the semen, with a nadir by day 61 in plasma and day 68 in semen.
These plasma findings contrast somewhat with our model; however, it appears their
models were overparametrized given their sample size, and also featured 2 knots (at days
18 and 60.66 for plasma) [38]. This likely explains the discrepancies with our current
findings. It is unclear how these knots were chosen, but our data and that of others, as
previously discussed, support a single knot at 100 days.

Following seroconversion, our model shows a steep decline in CSF viral load in
the first 100 days of infection, after which viral load slowly increases. In comparison with
the established model for viral dynamics in the plasma, our CSF model follows the same
general trajectory but at lower absolute levels of viral load [69]. Our findings support and
clarify the timing of the early spread of HIV to the CNS, where the virus has been shown
to cause CNS immune activation during primary infection [44] and later undergoes
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replication independent of that occurring in plasma [70, 71]. This further contextualizes
the neurological symptoms sometimes seen during primary HIV infection.

We found that blood CD4/CD8 ratio is significantly negatively associated with
HIV viral load throughout the first 3 years of natural infection. This complements prior
results from a study of the RV254/SEARCH010 cohort, where the authors found an
independent correlation between CD4/CD8 ratio and CSF HIV RNA during acute
infection in individuals prior to initiation of ART [72]. Moreover, a declining CD4/CD8
ratio has been found to be associated with neurocognitive deterioration independent from
viral replication [73]. Even in individuals without HIV, a low CD4/CD8 ratio is a marker
of the ‘immune risk phenotype,’ which itself is associated with increased morbidity and
mortality [74]. Thus it is understandable that our model showed a long-term decline in
the CD4/CD8 ratio in ART-naïve participants.

A major strength of this study is the prospective follow-up of participants
identified early after seroconversion. The participants underwent cognitive testing, CSF
sampling, and blood draws at follow-up visits as permitted, resulting in an extensive
observational dataset of CNS and systemic measures in primary HIV infection from its
early stages. Longitudinal observation of ART-naïve participants was possible because
data collection for most participants occurred when the standard of care was to initiate
ART only at specific CD4+ T cell count thresholds (fewer than 350 CD4+ T cells/μL) or
in the setting of opportunistic infections or other conditions attributable to HIV infection.
Given current guidelines for initiating treatment immediately in all individuals with an
HIV infection [75], it would be ethically impermissible to recreate such a cohort and

30
dataset. As a result, this dataset provides an entirely unique resource for an understanding
of the natural history of early HIV infection of the CNS.

This study has a few limitations, including the decreasing number of CSF
measurements available for analysis later in the course of infection, as participants either
left the study or initiated ART. However, our estimation method allowed us to keep all
participants in the analysis, regardless of loss to follow up. Another potential limitation is
the relative lack of female participants included in the overall cohort, as the PISCES
cohort is predominantly composed of men, although we do not have evidence that either
gender or sexuality plays a role in HIV viral dynamics. The reason for this sex imbalance
is that recruitment for the San Francisco cohort (of which 75% of our final cohort was
composed) occurred at a community clinic which primarily served men who have sex
with men. In contrast, recruitment for the Gothenburg cohort occurred following clinical
referral to an infectious disease specialist.

As this project only studied the CSF of participants who remained ART-naïve, we
must consider whether initiation of ART in select individuals could have skewed the
results; e.g., it is possible that those individuals who began ART had CSF viral load
trajectories that differed significantly from those who were included in the study.
However, the majority of participants in the overall cohort who began ART did so of
their own choosing, before they met the clinical guidelines for initiation at that time,
making it less likely that the exclusion of their CSF viral loads from this study after
initiation would systemically skew the remaining data.
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The ICC for our parametrized model indicates that there is likely inherent
variability between subjects, though it is possible that there is another variable not
included in the model which may account for the total variance observed. As the
trajectory of CSF viral load is quite similar to that of plasma viral load, we examined the
possibility of plasma viral load being such a contributing variable, but found the plasma
viral load to be fully colinear with time in our model. This means that, for the
parametrized model, time since infection and plasma viral load are equally important in
determining the CSF viral load; as such, plasma viral load was not included as a
parameter.

While this analysis describes the longitudinal trajectory of CSF HIV viral load, it
cannot help us conclude whether the presence of HIV in the CSF is due to continued
trafficking of HIV across the BBB versus sustained HIV replication within the CSF after
initial viral translocation. Recent research has shown evidence of HIV replication in
CD4+ T cells within the CSF during acute infection, suggesting that the viral load seen in
the CSF originates from these T cells and not from a translocation of free virus across the
BBB [76]. Findings such as these are important to contextualize our results, as they shed
light on the mechanism behind establishment of this viral reservoir.

As previously mentioned, the PISCES cohort has been used in other studies to
investigate CNS inflammation during primary HIV infection. Young et al. found
increases in choline/creatine-containing metabolites in frontal white matter and increases
in myo-inositol/creatine in parietal gray matter during the first year of infection, which
attenuated (but did not reverse) following ART initiation, indicating ongoing
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inflammation and gliosis in those areas which is likely irreversible even on adequate
treatment. They also noted elevated baseline glutamate/creatine in the basal ganglia, with
a subsequent decrease following ART initiation, indicating that the glutamate toxicity
caused by HIV can potentially be reversed with prompt therapy [77].

In a separate analysis of the same cohort used in this project (participants from
San Francisco, USA and Gothenburg, Sweden), Suh et al. reported progressive increases
in CSF neopterin and activated CD4+ and CD8+ T cells, which indicate increasing CNS
inflammation during primary HIV infection in ART-naïve individuals [22]. Peluso et al.,
in a study involving this cohort in addition to participants from Sydney, Australia and
Milan, Italy, found elevated neurofilament light chain and decreased MRS metabolites
when compared with controls, indicating neuronal injury during primary HIV infection
[19].

Another earlier analysis using the same cohorts found that during early HIV
infection (at a median of 77 days post-transmission), individuals had CSF viral loads,
white blood cell counts, and neopterin and CXCL10 chemokine levels similar to those
seen during chronic HIV infection [44]. Thus, our results add to the growing body of
evidence – from studies of this cohort and others – that HIV enters the CNS early in
infection and persists there longitudinally, and thus may contribute to further
neuropathogenesis. The continued presence of HIV in the CNS results in the
establishment of a reservoir for HIV, as well as neurological injury, cognitive and mood
impairment, thus making a more complete understanding of this reservoir crucial for
future efforts at a complete cure.
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Further areas of study could include using other variables as covariates, such as
neurocognitive function, CSF inflammatory markers, or CNS metabolites. Additionally,
modeling CSF viral dynamics following initiation of ART could help better inform the
process behind CSF escape.
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